Sugi Predict

Sugi Predict / Compounds / SCHEMBL589746

SCHEMBL589746

SCHEMBL589746

CCN1CCCN(c2ccc(C(=O)Nc3nn(C(c4ccccc4)(c4ccccc4)c4ccccc4)c4ccc(S(=O)(=O)c5cc(F)cc(F)c5)cc34)c(N)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 11/20 0.43
▸ INSR P06213 10/20 0.43
▸ IGF1R P08069 8/20 0.43
▸ AURKA O14965 3/20 0.35
▸ AURKB Q96GD4 3/20 0.35
▸ DRD3 P35462 2/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ TSHR P16473 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ PLK4 O00444 2/20 0.34
▸ DAPK3 O43293 2/20 0.34
▸ NTRK1 P04629 2/20 0.34
▸ PRKCG P05129 2/20 0.34
▸ ROS1 P08922 2/20 0.34
▸ FER P16591 2/20 0.34
▸ LTK P29376 2/20 0.34
▸ FRK P42685 2/20 0.34
▸ MST1R Q04912 2/20 0.34
▸ PTK2 Q05397 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL590559 0.92 ALK (0.46) ALKINSRIGF1RAURKAAURKB
SCHEMBL590368 0.91 ALK (0.35) ALKINSRIGF1RDRD3TSHR
SCHEMBL592137 0.90 ALK (0.48) ALKINSRIGF1RAURKAAURKB
SCHEMBL589594 0.85 ALK (0.39) ALKINSRIGF1RAURKAAURKB
SCHEMBL590468 0.83 SIRT6 (0.40) ALKINSRIGF1RAURKAAURKB
SCHEMBL590550 0.82 HDAC1 (0.39) HRH3MET
SCHEMBL590369 0.82 ALK (0.37) ALKINSRIGF1RMAPT
SCHEMBL592048 0.81 SIRT6 (0.42) ALKINSRIGF1RPLK4DAPK3
SCHEMBL589615 0.80 IGF1R (0.48) ALKINSRIGF1RAURKAAURKB
SCHEMBL592098 0.79 ALK (0.31) ALKINSRIGF1RTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120932-B1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2014-07-09 — — EP disclosed
US-8114865-B2 Indazole derivatives as kinase inhibitors for the treatment of cancer NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-14 — — US disclosed
US-20100197665-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-08-05 — — US disclosed
EP-2120932-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Nerviano Medical Sciences S.r.l. (IT) 2009-11-25 — — EP disclosed
WO-2008074749-A9 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2009-05-07 — — WO disclosed
WO-2008074749-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197665-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER MAP3K5, MAP3K19, MAP3K3 ALK 420/4885INSR 400/4885IGF1R 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.